PubMed · 14127099
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
V STANCANELLI. 1964-01-06. [AORTOCLYSIS. TECHNICAL NOTE].. https://pubmed.ncbi.nlm.nih.gov/14127099/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
BACKGROUND: A dextran sulfate column (Liposorber) has been developed and proven effective in LDL apheresis for removing LDL from patients with hyperlipemia. Chronic renal failure (CRF) patients with arteriosclerosis obliterans (ASO) treated with Liposorber have been shown good results. METHODS: We analyzed proteins absorbed by Liposorber in CRF patients with ASO by means of 2-dimensional electrophoresis and found some noteworthy protein spots. One of these proteins was purified by Sephacryl S-100 column and DEAE Sepharose fast flow column chromatography. RESULTS: The purified protein was finally identified as complement factor D by Western blotting. The average of recovery amount from three experiments was 6.5 mg. The total recovered amount of factor D was calculated to be about 21.7% out of the estimated amount of factor D in the plasma of CRF patients with ASO receiving LDL apheresis using Liposorber. CONCLUSIONS: These results indicate that Liposorber absorbs factor D remarkably well.
The measurement of the ankle-brachial index (ABI) or the ankle/arm ratio provides a simple, rapid and cheap method for the evaluation of the distal perfusion of lower limbs. A decreased value underlines an altered arterial state. Thus, ABI is an excellent marker of peripheral arterial disease, even prior to the occurrence of functional symptoms. Beyond the diagnosis of peripheral arterial disease, ABI is nowadays known as a marker of atherosclerosis and a cardiovascular marker. Hence, ABI appears not only as a tool in the functional assessment of lower limbs perfusion, but also a local and general marker of atherosclerosis and cardiovascular events. The aim of this paper is to update data on the usefulness of ABI through a general review, and to present open issues. After a focus on the methodology of ABI measurement, the diagnostic value of ABI will be presented in this paper.
Vascular endothelial growth factor (VEGF) strongly promotes angiogenesis, and monocyte-colony stimulating factor (M-CSF) regulates the differentiation, proliferation, and survival of monocytes. Both VEGF and M-CSF are expressed in atherosclerotic lesions. The present study was performed to clarify the role of VEGF and M-CSF in the development of peripheral artery disease (PAD). The serum VEGF and M-CSF concentrations were determined in patients with arteriosclerosis obliterans (ASO) and thromboangitis obliterans (TAO). In both patient groups the serum VEGF concentrations were significantly higher than those in the control subjects. In contrast, the serum M-CSF concentrations in the ASO patients were significantly higher than those in both the TAO patients and control subjects, but there were no differences in the M-CSF concentrations between the TAO patients and control subjects. There was no correlation between the serum concentrations of VEGF and M-CSF. In conclusion, the serum VEGF concentration was increased in ASO and TAO patients, but increased concentration of M-CSF was seen only in ASO patients. These results may reflect a difference between ASO and TAO in disease pathogenesis.